Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

MELBOURNE, Australia, Aug. 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.

This Phase 2b trial is evaluating the efficacy, safety and tolerability of two dose levels of a single application of DeOvo™ compared to vehicle. The trial consists of treating 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the United States.

Hatchtech's proprietary product DeOvo™ is a topical formulation of a known metalloprotease inhibitor which targets proteases that are key to biological processes involved in insect hatch and survival.

Hatchtech Chairman Dr Paul Kelly commented: "We continue to be encouraged by Hatchtech's progress with its next generation head lice product DeOvo™ in line with our business objectives. The recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned."

"In the US it is estimated that 6-12 million people, mainly children aged 3-12 years, are infested each year with head lice (Pediculus humanus capitis). With the emergence of drug resistant lice and often poor efficacy of existing products, this under-served market represents a substantial commercial opportunity." Company Contact

Media InquiriesDr Paul Kelly

Dr Vern BowlesChairman

Chief Scientific Officer+61 (2) 8205-7379

+61 (0) 400 673 938pkelly@one-ventures.com

vbowles@hatchtech.com.auAbout the TrialThe following information is provided in accord with the AusBiotech/ASX Code of Best Practice for Reporting by Life Sciences Companies.Name of TrialHa02-003Blinding StatusDouble-blindPlacebo ControlledRandomized, vehicle-controlledDesignP
'/>"/>

SOURCE Hatchtech Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... with the prior year. Reported sales decreased 4% as ... , Net earnings per diluted share as reported ... period. Adjusted EPS was $2.80 , an increase ...
(Date:7/30/2015)... July 30, 2015 IRIDEX Corporation (NASDAQ: ... second quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, August 6, 2015 ... other business developments. Interested parties may access ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:7/31/2015)... Wilmington, DE (PRWEB) , ... July 31, 2015 ... ... long term care client base, with the recent implementation of Microsoft Dynamics GP ... provider in the industry, Intellitec is now supporting senior living communities in 16 ...
(Date:7/30/2015)... ... ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the first cannabis ... at the Caribe Royal All Suites Hotel and Convention Center in Orlando, Florida, October ... medical cannabis expo in the country and this year’s expo will be the first ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a vertically ... invention that can help people during emergencies. , "The worldwide mobile health market ... Director of World Patent Marketing. "Currently, there are about 97,000 mobile health apps ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The connection between a healthy head of ... The loss of a full head of hair can have a devastating impact on ... person is perceived in the work place, the consequences of hair loss are not to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... region, is the recipient of three awards in the Service Industry Advertising Awards ... created for Choptank Transport, KRM Development Corporation and University of Maryland Shore Regional ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3
... Oct. 17 ImClone Systems,Incorporated (Nasdaq: IMCL ... ),today announced that they have established an agreement ... ERBITUX(R) (cetuximab) in,Japan. Under the terms of the ... collaborate on a joint effort to develop and,following ...
... Bickley wins CBay,s ,Keys to Medical ... Records Success, sweepstakes, ... transcription and healthcare BPO services, today announced the winner of,its ... and Exhibit in Philadelphia. (Photo: http://www.newscom.com/cgi-bin/prnh/20071017/NEW009 ) ...
... following is a,transcript of remarks by President Bush, Senator ... afternoon. Thanks for coming. Welcome to the Rose,Garden. I ... their commission for joining me today. Welcome. I ... and Acting,Secretary Mansfield -- with service members who were ...
... At the U.S. Food and Drug,Administration,s ... today, the majority of members voted to ... Pharmaceuticals, non-calcium FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia ... chronic kidney disease (CKD) Stage 4 patients.,Currently, ...
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... (NASDAQ: ASPV ; TSX: ASV) today announced ... million for the third,quarter of 2007 compared to ... 2006. As previously announced, Aspreva will release ... The Company will hold a conference,call and webcast ...
Cached Medicine News:Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7Health News:CBaySystems Gives Away 2008 Honda Civic at AHIMA 2007 2Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 2Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 3Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 4Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 5Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 6Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 7Health News:Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for America's Returning Wounded Warriors Report Implementation 8Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: